Literature DB >> 19195049

Capturing coping with symptoms in people with a diagnosis of schizophrenia: introducing the MACS-24.

Maarten Bak1, Philippe Delespaul, Lydia Krabbendam, Karola Huistra, Wil Walraven, Jim van Os.   

Abstract

In order to assess coping with psychotic symptoms, the Maastricht Assessment of Coping Strategies (MACS), 24 symptom version, was developed as a refinement of the previous MACS-13. Associations between type of coping and the experienced level of control over psychotic symptoms were examined using MACS-24.MACS-24 was administered to 32 individuals with a diagnosis of schizophrenia. For each of 24 symptoms, experience of distress, type of coping and the resulting degree of perceived control were assessed. Coping types were reduced to two contrasting coping factors: symptomatic coping and non-symptomatic coping (combining active problem solving, passive illness behaviour, active problem avoiding, and passive problem avoiding).Mean level of distress and perceived control (range: 1-7) were, respectively, 4.2 [standard deviation (SD) = 1.9] and 4.2 (SD = 1.9). The association between distress and perceived control was negative [beta = -0.28; 95% confidence interval (95%CI) = -0.41 to -0.15]. Type of coping interacted with perceived control (p = 0.005), in that symptomatic coping was negatively associated with perceived control [odds ratio (OR) over seven levels = 0.82, 95%CI = 0.71-0.94], whereas for non-symptomatic coping a positive association was apparent (OR over seven levels = 1.10, 95% CI = 1.03-1.19).Previous contrasts between symptomatic and non-symptomatic coping were replicated using MACS-24, suggesting clinical validity and utility.

Entities:  

Mesh:

Year:  2009        PMID: 19195049      PMCID: PMC6878384          DOI: 10.1002/mpr.272

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  42 in total

1.  Maastricht Assessment of Coping Strategies (MACS-I): a brief instrument to assess coping with psychotic symptoms.

Authors:  M Bak; F van der Spil; N Gunther; S Radstake; P Delespaul; J van Os
Journal:  Acta Psychiatr Scand       Date:  2001-06       Impact factor: 6.392

2.  Coping style and cognitive dysfunction in schizophrenic patients.

Authors:  R J van den Bosch; M J van Asma; R Rombouts; J W Louwerens
Journal:  Br J Psychiatry Suppl       Date:  1992-10

3.  Acting on voices: Omnipotence, sources of threat, and safety-seeking behaviours.

Authors:  David Hacker; Max Birchwood; Jeremy Tudway; Alan Meaden; Catherine Amphlett
Journal:  Br J Clin Psychol       Date:  2007-10-23

4.  Multidimensional assessment of coping: a critical evaluation.

Authors:  N S Endler; J D Parker
Journal:  J Pers Soc Psychol       Date:  1990-05

5.  Personal coping styles of schizophrenic outpatients.

Authors:  C I Cohen; L A Berk
Journal:  Hosp Community Psychiatry       Date:  1985-04

6.  Coping with hallucinations: exploring stress and coping framework.

Authors:  J Farhall; M Gehrke
Journal:  Br J Clin Psychol       Date:  1997-05

7.  Personality dimensions in schizophrenia: associations with symptoms and coping.

Authors:  Paul H Lysaker; Marcia A Wilt; Cynthia D Plascak-Hallberg; Colleen A Brenner; Catherine A Clements
Journal:  J Nerv Ment Dis       Date:  2003-02       Impact factor: 2.254

Review 8.  Remission in schizophrenia: proposed criteria and rationale for consensus.

Authors:  Nancy C Andreasen; William T Carpenter; John M Kane; Robert A Lasser; Stephen R Marder; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

9.  When does experience of psychosis result in a need for care? A prospective general population study.

Authors:  Maarten Bak; Inez Myin-Germeys; Manon Hanssen; Rob Bijl; Wilma Vollebergh; Philippe Delespaul; Jim van Os
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems.

Authors:  V Peralta; M J Cuesta; J de Leon
Journal:  Psychol Med       Date:  1995-01       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.